Endoscopic transsphenoidal surgery increases gross total resection rates for pituitary tumors compared to microscopic techniques
Endoscopic surgery shows higher removal rates for pituitary tumors
This meta-analysis of 26,295 patients compares endoscopic and microscopic transsphenoidal pituitary surgery. The analysis found higher rates…
Doctors find that endoscopic surgery helps remove more of a pituitary tumor while keeping the same level of safety as traditional methods.
Surgical treatment and multimodal therapies characterize management options for rare penile melanoma cases
Treatment Options and Clinical Features for Penile Melanoma
This case series and narrative review describes the clinical features and treatment landscape for patients with penile melanoma. The authors…
New research highlights surgical options and targeted therapies for penile melanoma, a rare form of skin cancer that primarily affects middl…
HR-positive HER2-low breast cancer accounts for 60% of cases; deruxtecan reshapes treatment
New drug class reshapes treatment for common breast cancer type
This systematic review examines HR-positive HER2-low-expressing breast cancer, noting it accounts for nearly 60% of breast cancer incidence.…
Nearly 60% of breast cancers are HR-positive HER2-low. A new drug class is changing how they're treated.
Indefinite-duration lenalidomide maintenance shows no significant difference in overall survival compared to fixed-duration
Trial compares continuous versus fixed duration lenalidomide for myeloma
This Phase 3 randomized trial of 516 patients with standard-risk newly diagnosed multiple myeloma found that indefinite-duration lenalidomid…
A large trial found that continuing lenalidomide treatment indefinitely did not improve overall survival compared to a fixed two-year plan.
AI plus celecoxib more than doubles odds of clinical response in ER-positive breast cancer
Adding celecoxib to hormone therapy improves early breast cancer response
This Phase III randomized trial of 269 postmenopausal women with ER-positive resectable breast cancer found that adding celecoxib to an arom…
A new trial shows that adding the drug celecoxib to standard hormone therapy can improve initial clinical responses in postmenopausal women …
BIRC3::MALT1 fusion detected in 35% of cells in pulmonary MALT lymphoma case
Case Report Shows Pulmonary MALT Lymphoma Diagnosis in Lung Nodule
This case report describes a 49-year-old man with pulmonary MALT lymphoma and a BIRC3::MALT1 fusion. The report highlights that mild FDG upt…
A rare type of lymphoma was identified in a 49-year-old man, highlighting the importance of tissue samples when interpreting imaging results…
Artificial intelligence improves diagnostic accuracy and treatment planning in prostate cancer management
Artificial Intelligence Shows Potential for Prostate Cancer Diagnosis and Treatment
This narrative review examines the role of artificial intelligence in diagnosing and treating prostate cancer. The authors conclude that AI-…
New research explores how artificial intelligence can improve the accuracy of prostate cancer diagnosis and help create more personalized tr…
AI diagnostic tools show high accuracy but limited real-world validation in systematic review
Artificial intelligence shows high accuracy in detecting various medical conditions
This systematic review of 24 studies synthesizes evidence on AI and deep learning for disease detection across multiple imaging modalities. …
New analysis of 24 studies shows AI tools can reach over 90% accuracy in spotting everything from lung cancer to skin disorders.
Metabolic reprogramming of chondrocytes through impaired oxidative phosphorylation contributes to articular cartilage collapse
Cells' energy crisis may drive osteoarthritis cartilage collapse
This systematic review synthesizes literature regarding metabolic reprogramming in chondrocytes during osteoarthritis. The authors conclude …
Osteoarthritis may be fueled by a cellular energy crisis, not just wear and tear. A new review suggests targeting metabolism could lead to n…
FDA Approves Retevmo (selpercatinib) for RET-Driven Cancers
FDA approves new drug Retevmo for certain lung and thyroid cancers.
FDA approved Retevmo (selpercatinib) for adult and pediatric patients with RET fusion-positive NSCLC, RET-mutant MTC, RET fusion-positive th…
The FDA approved Retevmo (selpercatinib) for adults with a type of lung cancer that has a specific gene change, and for children and adults …
FDA Approves Retevmo (selpercatinib) for RET Fusion-Positive Solid Tumors
FDA approves Retevmo for more cancers with RET gene fusions
The FDA approved Retevmo (selpercatinib) for adult and pediatric patients 2 years and older with RET fusion-positive solid tumors that have …
The FDA approved Retevmo (selpercatinib) for adults and children ages 2 and older with advanced solid tumors that have a RET gene fusion and…
Olanzapine containing regimens consistently improve complete response across all phases of chemotherapy-induced nausea and vomiting
Olanzapine helps manage nausea and vomiting during chemotherapy treatment
This network meta-analysis of 10,455 adults receiving chemotherapy found that olanzapine-containing regimens consistently improved complete …
New data shows olanzapine can effectively control nausea and vomiting for patients undergoing chemotherapy, with lower doses showing similar…